Trial Profile

A single arm open label study of B-VEC eyedrops for ocular complications of DEB

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Beremagene geperpavec (Primary)
Indications Epidermolysis bullosa dystrophica
Focus Adverse reactions; Registrational
Acronyms IOLITE

Most Recent Events

06 May 2025 According to a Krystal Biotech media release, the Company expects to dose the first patient in the registrational KB803 Phase 3 IOLITE study later this month.
04 Nov 2024 According to a Krystal Biotech media release, study is expected to commence in 1H 2025.
05 Aug 2024 According to a Krystal Biotech media release, expected to commence in 4Q 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com